Legal & General Group
AUPH icon

Legal & General Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Legal & General Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
104,414
+4,141
+4% +$66.2K ﹤0.01% 2010
2026
Q1 		$1.48M Sell
100,273
-26,264
-21% -$384K ﹤0.01% 2026
2025
Q4 		$2.02M Sell
126,537
-14,454
-10% -$205K ﹤0.01% 1960
2025
Q3 		$1.59M Sell
140,991
-501
-0.4% -$5.47K ﹤0.01% 2076
2025
Q2 		$1.2M Buy
141,492
+20,027
+16% +$161K ﹤0.01% 2177
2025
Q1 		$977K Sell
121,465
-9,841
-7% -$79.7K ﹤0.01% 2193
2024
Q4 		$1.18M Buy
131,306
+3,426
+3% +$28K ﹤0.01% 2180
2024
Q3 		$937K Sell
127,880
-1,105
-0.9% -$6.85K ﹤0.01% 2253
2024
Q2 		$737K Sell
128,985
-2,774
-2% -$14.6K ﹤0.01% 2294
2024
Q1 		$660K Sell
131,759
-836
-0.6% -$5.67K ﹤0.01% 2326
2023
Q4 		$1.19M Buy
132,595
+1,558
+1% +$12.8K ﹤0.01% 2153
2023
Q3 		$1.03M Buy
131,037
+7,411
+6% +$72.5K ﹤0.01% 2180
2023
Q2 		$1.2M Buy
123,626
+331
+0.3% +$3.44K ﹤0.01% 2149
2023
Q1 		$1.35M Buy
123,295
+4,638
+4% +$40.9K ﹤0.01% 2052
2022
Q4 		$513K Buy
118,657
+1,877
+2% +$10.9K ﹤0.01% 2330
2022
Q3 		$878K Sell
116,780
-9,932
-8% -$86K ﹤0.01% 2181
2022
Q2 		$1.27M Buy
126,712
+36,383
+40% +$407K ﹤0.01% 2065
2022
Q1 		$1.12M Buy
90,329
+54,515
+152% +$843K ﹤0.01% 2210
2021
Q4 		$819K Sell
35,814
-4,298
-11% -$102K ﹤0.01% 2286
2021
Q3 		$841K Buy
40,112
+34,881
+667% +$554K ﹤0.01% 2286
2021
Q2 		$68K Hold
5,231
– – ﹤0.01% 2858
2021
Q1 		$68K Hold
5,231
– – ﹤0.01% 2729
2020
Q4 		$72K Hold
5,231
– – ﹤0.01% 2678
2020
Q3 		$77K Buy
5,231
+1,429
+38% +$20.7K ﹤0.01% 2562
2020
Q2 		$62K Hold
3,802
– – ﹤0.01% 2668
2020
Q1 		$55K Hold
3,802
– – ﹤0.01% 2563
2019
Q4 		$77K Buy
3,802
+1,483
+64% +$13.7K ﹤0.01% 2676
2019
Q3 		$12K Hold
2,319
– – ﹤0.01% 3238
2019
Q2 		$15K Hold
2,319
– – ﹤0.01% 3275
2019
Q1 		$15K Buy
+2,319
New +$15.4K ﹤0.01% 3166
2018
Q3 		– Sell
-2,329
Closed -$13K – 3388
2018
Q2 		$13K Hold
2,329
– – ﹤0.01% 3272
2018
Q1 		$12K Buy
+2,329
New +$12.5K ﹤0.01% 3193

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legal & General Group's AUPH Position: Q2 2026 in Review

Legal & General Group increased its Aurinia Pharmaceuticals (AUPH) stake by 4.1% in Q2 2026, buying an estimated $66.2K and bringing the position to 104,414 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

Legal & General Group first reported a position in AUPH in Q1 2018 and has held it in 32 quarters since. The position peaked at $2.02M in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Legal & General Group held 104,414 shares of Aurinia Pharmaceuticals worth $1.75M as of Q2 2026.
  • Legal & General Group bought 4,141 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $66.2K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2010 holding.
  • Legal & General Group first reported a position in Aurinia Pharmaceuticals in Q1 2018 and has held it in 32 quarters since.
  • Legal & General Group's Aurinia Pharmaceuticals position peaked at $2.02M in Q4 2025.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.